Company Profile

Company Name AntiCancer Technologies Inc.
English Name AntiCancer Technologies Inc. (Abbreviation: ACT)
Representative Director Hiroyuki Ochi
Capital 65,500,000 JPY
Date Established September 1, 2023
Business Activities
  • Research, development, manufacturing, and sales of pharmaceuticals, medical devices, etc.
  • Acquisition, licensing, and management of intellectual property rights, etc.
  • Joint research and development projects with government agencies, research institutions, companies, etc.
  • Business related to the collection, processing, analysis, and provision of various information
  • Wholesale, brokerage, agency, and import/export business related to the preceding items
  • Marketing and consulting related to the preceding items
  • All businesses incidental or related to the preceding items
Location 13F Pacific Century Place, 1-11-1 Marunouchi, Chiyoda-ku, Tokyo
Hiroyuki Ochi, President and CEO

President and CEO
Hiroyuki Ochi

1993

Joined Santen Pharmaceutical Co., Ltd.

2002

Engaged in product management within the Marketing Division of Santen Pharmaceutical Co., Ltd.

2009

Director, Santen Pharmaceutical Korea Co., Ltd.

2014

Director, Santen Pharmaceutical Taiwan Co., Ltd.

2019

Joined SanBio Co., Ltd.
As General Manager of the Regenerative Medicine Business Development Division, led business development, organizational development, marketing, and business initiatives toward regulatory approval and commercialization of Acurago, the world’s first regenerative medicine product for the brain.

2025

Concurrently appointed Secretary General of the Japan Biotech Association (through 2026).

2026

Appointed President and Representative Director, AntiCancer Technologies Inc.

Keiichi Nakayama, CSO

Chief Scientific Officer (CSO)
Keiichi Nakayama

1986

Graduated from Tokyo Medical and Dental University, School of Medicine

1990

Completed graduate studies in immunology at Juntendo University Graduate School of Medicine (MD, PhD)

1995

Principal Researcher at Nippon Roche K.K.

1996

Professor at the Medical Institute of Bioregulation, Kyushu University

2021

Medal with Purple Ribbon

2023

Distinguished Professor at the Institute for Advanced Study, Tokyo Medical and Dental University

2024

Distinguished Professor at the Institute for Advanced Study, Tokyo Institute of Science and Technology

Tsugutoshi Kikuchi, COO

Chief Operating Officer (COO)
Tsugutoshi Kikuchi

1995

Graduated from the University of Chicago Booth School of Business (MBA Program)

1997–2002

Representative Director, Le Cordon Bleu Japan

2004–2007

Director, Apple Japan; Head of Apple Store

2007–2023

Regional Online Manager, Microsoft Japan

2023

Certified Sake Lecturer by the Food & Beverage Specialists Organization (FBO)

Ryuhei Okada, Assistant Professor, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University

Assistant Professor, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
Ryuhei Okada

2009

Graduated from Tokyo Medical and Dental University, School of Medicine

2017

Completed graduate studies at Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences (Clinical Anatomy)

2018

Engaged in basic research in the Molecular Imaging Branch, National Cancer Institute, USA

2021

Assistant Professor, Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University

History

September 1, 2023: AntiCancer Technologies Inc. established jointly by Distinguished Professor Keiichi Nakayama of Tokyo Medical and Dental University, Dr. Teruyasu Nishino, Mr. Takafumi Horie, and others.
October 24, 2023: Filed basic patent for Pipeline 1.
February 21, 2024: Certified as a "Tokyo Medical and Dental University Startup" by Tokyo Medical and Dental University.
October 7, 2024: Selected as the 11th support recipient of the "1stRound" entrepreneurship support program by UTokyo Innovation Platform Co., Ltd. (UTokyo IPC).